MDCX
Medicus Pharma Ltd. Common StockMDCX
MDCX
About: Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.
Employees: 12
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
202% more capital invested
Capital invested by funds: $3.74M [Q4 2024] → $11.3M (+$7.57M) [Q1 2025]
100% more funds holding
Funds holding: 3 [Q4 2024] → 6 (+3) [Q1 2025]
9.95% more ownership
Funds ownership: 12.72% [Q4 2024] → 22.67% (+9.95%) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$20
669%
upside
Avg. target
$24
804%
upside
High target
$27
938%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
D. Boral Capital Jason Kolbert | 938%upside $27 | Buy Maintained | 9 Jun 2025 |
Maxim Group Jason McCarthy | 669%upside $20 | Buy Maintained | 8 May 2025 |
Financial journalist opinion
Based on 11 articles about MDCX published over the past 30 days
Positive
Proactive Investors
2 days ago
Medicus Pharma targets horse cancer with new trial – ICYMI
Medicus Pharma (NASDAQ:MDCX) earlier this week announced the submission of a veterinary clinical development program to the FDA targeting squamous cell carcinoma in horses. The move follows the company's receipt of an orphan drug designation for the condition from the veterinary division of the agency.
Neutral
Newsfile Corp
4 days ago
Medicus Pharma Ltd. to Present at 2025 Bio International Convention
Company Executive Chairman & CEO to Provide Corporate Updates on June 17th 2025 Philadelphia, Pennsylvania--(Newsfile Corp. - June 12, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce the schedule of the presentation of Dr. Raza Bokhari, Executive Chairman and CEO, at 2025 Bio International Convention.
Neutral
Proactive Investors
6 days ago
Medicus Pharma submits FDA plan to develop microneedle-based treatment for skin cancer in horses
Medicus Pharma (NASDAQ:MDCX) said on Monday it has submitted a comprehensive product development plan to the US Food and Drug Administration (FDA) to advance its investigational treatment for external squamous cell carcinoma (SCC) in horses. The plan was submitted under the company's existing Investigational New Animal Drug file and follows the FDA's Minor Use in Major Species designation, which Medicus received in December 2024 for its dissolvable Doxorubicin-containing microneedle array (D-MNA).
Neutral
Newsfile Corp
1 week ago
Medicus Pharma Ltd. Announces Submission of Product Development Plan to the Food and Drug Administration (FDA) to Treat External Squamous Cell Carcinoma (SCC) in Horses
Company Is Advancing Use of Novel Doxorubicin-containing Microneedle Array (D-MNA) Patch in Veterinary Oncology as an Orphan Drug Philadelphia, Pennsylvania--(Newsfile Corp. - June 9, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce submission of a comprehensive product development plan to treat external squamous cell carcinoma (SCC) under Investigational New Animal Drug (INAD File No.013880).
Positive
Proactive Investors
1 week ago
Medicus Pharma appoints KPMG as new auditor, expands global clinical programs
Medicus Pharma (NASDAQ:MDCX) said it has appointed KPMG as its independent registered public accounting firm for the 2025 fiscal year, replacing EisnerAmper following a review process led by the company's audit committee and approved by its board. The transition, announced on June 4, comes as the clinical-stage biotech company ramps up its global operations and research programs.
Neutral
Newsfile Corp
1 week ago
Medicus Pharma Ltd. Announces Closing of $7.0 Million Public Offering
Philadelphia, Pennsylvania--(Newsfile Corp. - June 2, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) (the "Company") today announced the closing of its previously announced public offering of 2,260,000 units, on a "best-efforts" basis, at a price of $3.10 per unit.
Neutral
Proactive Investors
2 weeks ago
Medicus Pharma unveils pricing of $7M public offering
Medicus Pharma (NASDAQ:MDCX) has announced the pricing of its $7 million public offering of 2.26 million shares on a “best-efforts” basis at $3.10 per unit. Each unit includes one share and one warrant to purchase a share at an exercise price of $3.10, with the warrants expiring five years from the date of issuance and not trading on any securities exchange.
Neutral
Newsfile Corp
2 weeks ago
Medicus Pharma Ltd. Announces Pricing of $7.0 Million Public Offering
Philadelphia, Pennsylvania--(Newsfile Corp. - May 29, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) (the "Company") today announced the pricing of its public offering of 2,260,000 units, on a "best-efforts" basis, at a price of $3.10 per unit.
Positive
Proactive Investors
3 weeks ago
Medicus Pharma begins UAE cancer trial expansion – ICYMI
Medicus Pharma (NASDAQ:MDCX) CEO Raza Bokhari talked with Proactive about the company's newly announced regulatory approval to expand its Phase 2 trial into the United Arab Emirates. The study is focused on a noninvasive therapy for basal cell carcinoma (BCC), the most common form of cancer globally.
Positive
Proactive Investors
3 weeks ago
Medicus Pharma gets UAE approval for Phase 2 study for skin cancer therapy
Medicus Pharma (NASDAQ:MDCX) has received regulatory approval from the UAE Department of Health to begin a Phase 2 clinical trial evaluating its non-invasive therapy for basal cell carcinoma (BCC) of the skin. The study, designated SKNJCT-004, will enroll up to 36 patients across four medical centers in the UAE.
Charts implemented using Lightweight Charts™